Genocea Biosciences Stock Price To Earning

GNCADelisted Stock  USD 0.0002  0.0001  100.00%   
Genocea Biosciences fundamentals help investors to digest information that contributes to Genocea Biosciences' financial success or failures. It also enables traders to predict the movement of Genocea Stock. The fundamental analysis module provides a way to measure Genocea Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genocea Biosciences stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Genocea Biosciences Company Price To Earning Analysis

Genocea Biosciences' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

 = 

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Current Genocea Biosciences Price To Earning

    
  (0.59) X  
Most of Genocea Biosciences' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genocea Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition

Based on the latest financial disclosure, Genocea Biosciences has a Price To Earning of -0.59 times. This is 102.28% lower than that of the Biotechnology sector and 111.97% lower than that of the Health Care industry. The price to earning for all United States stocks is 102.05% higher than that of the company.

Genocea Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genocea Biosciences' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genocea Biosciences could also be used in its relative valuation, which is a method of valuing Genocea Biosciences by comparing valuation metrics of similar companies.
Genocea Biosciences is currently under evaluation in price to earning category among its peers.

Genocea Fundamentals

About Genocea Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Genocea Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genocea Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genocea Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Consideration for investing in Genocea Stock

If you are still planning to invest in Genocea Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genocea Biosciences' history and understand the potential risks before investing.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Fundamental Analysis
View fundamental data based on most recent published financial statements
CEOs Directory
Screen CEOs from public companies around the world
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals